FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

FOCUS ON RESEARCH Previous Volume 354:789-790 February 23, 2006 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Joensuu, H. PubMed Citation

Translation, translation, translation. Around the halls of academic medicine, translation is the mantra of the moment. In the literary world, translation is the process of interpreting an extant body of written work and converting it into a new language. In the scientific world, translation is the application of fundamental discoveries in basic science to clinical medicine, with the goal of developing new treatments for debilitating diseases.

In this arena, the development of a humanized monoclonal antibody against the HER2 protein (trastuzumab, or Herceptin) as adjuvant therapy for early HER2-positive breast cancer ranks as one of the most satisfying and powerful . . . [Full Text of this Article]

Source Information

Dr. Chien is the director of the Cardiovascular Research Center, Massachusetts General Hospital, and a professor at Harvard Medical School — both in Boston.

This article has been cited by other articles:

• Rayson, D., Richel, D., Chia, S., Jackisch, C., van der Vegt, S., Suter, T. (2008). Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 19: 1530-1539 [Abstract] [Full Text]  
• Suter, T. M., Procter, M., Piccart, M. J. (2008). In Reply. JCO 26: 2053-2054 [Full Text]  
• Sengupta, P. P., Northfelt, D. W., Gentile, F., Zamorano, J. L., Khandheria, B. K. (2008). Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads. Mayo Clin Proc. 83: 197-203 [Abstract] [Full Text]  
• Bentzen, S. M., Trotti, A. (2007). Evaluation of Early and Late Toxicities in Chemoradiation Trials. JCO 25: 4096-4103 [Abstract] [Full Text]  
• Telli, M. L., Hunt, S. A., Carlson, R. W., Guardino, A. E. (2007). Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility. JCO 25: 3525-3533 [Abstract] [Full Text]  
• Hudis, C. A. (2007). Trastuzumab -- Mechanism of Action and Use in Clinical Practice. NEJM 357: 39-51 [Full Text]  
• Coudert, B. P., Largillier, R., Arnould, L., Chollet, P., Campone, M., Coeffic, D., Priou, F., Gligorov, J., Martin, X., Trillet-Lenoir, V., Weber, B., Bleuse, J. P., Vasseur, B., Serin, D., Namer, M. (2007). Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2 Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial. JCO 25: 2678-2684 [Abstract] [Full Text]  
• Spector, N. L., Yarden, Y., Smith, B., Lyass, L., Trusk, P., Pry, K., Hill, J. E., Xia, W., Seger, R., Bacus, S. S. (2007). Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc. Natl. Acad. Sci. USA 104: 10607-10612 [Abstract] [Full Text]  
• Chung, K. Y., Walker, J. W. (2007). Interaction and Inhibitory Cross-Talk between Endothelin and ErbB Receptors in the Adult Heart. Mol. Pharmacol. 71: 1494-1502 [Abstract] [Full Text]  
• Hoshijima, M., Knoll, R., Pashmforoush, M., Chien, K. R. (2006). Reversal of Calcium Cycling Defects in Advanced Heart Failure: Toward Molecular Therapy. J Am Coll Cardiol 48: A15-A23 [Abstract] [Full Text]